1Overview — genes, deafness & the implant
Every cochlear-implant candidate shares one diagnosis — severe-to-profound sensorineural hearing loss — yet their results vary enormously. A large part of that variation is written in the genome. Deafness is the commonest congenital sensory defect, about half of it genetic, and the particular gene at fault does more than explain how a person became deaf: it tells you where in the ear the lesion sits, and therefore whether the structure a cochlear implant actually stimulates — the spiral ganglion — is intact. This chapter is about reading that genetic information, and about the shift it brings: from explaining deafness after the fact to predicting the implant's result before surgery.
FWhat this chapter is
The previous chapters built up the ear, the brain, the population, and the causes of hearing loss. This one zooms into the molecular cause — the genes whose mutation produces deafness — and connects them to the question that matters most in this atlas: how well will a cochlear implant work? It is a bridge chapter, sitting between the foundations and the clinical work of candidacy, because genetics is increasingly part of the evaluation of every implant candidate.
It complements, rather than repeats, the population genetics of Chapter 5 (consanguinity and the founder mutations that make recessive deafness common in India). Here the lens is molecular and clinical: which genes, what they do, how to test for them, and what their failure predicts for the implant.
FHow common, and how genetic
Hearing loss is diagnosed in roughly 1 of every 500 newborns, making it the most common congenital sensory defect — several times more frequent than conditions like Down syndrome or cystic fibrosis. About half of congenital sensorineural loss is genetic; the rest is environmental (congenital CMV, perinatal injury, ototoxicity). Of the genetic half, around 70% is non-syndromic — deafness as the only finding — and 30% syndromic.[2005, 2006]
FTWhy the cause matters
Although every candidate carries the same audiological label, the causes are wildly heterogeneous — and that heterogeneity is almost certainly part of why implant outcomes spread so widely. Two children with identical audiograms and identical devices can diverge, and one reason is that their deafness began in different places: one in the cochlea, the other in the nerve. If we knew the cause, we could predict the result better — and increasingly, we can.[2014]
TThe organising idea
The thread running through the whole chapter is simple to state: the gene predicts the site of the lesion, and the site predicts the outcome. A cochlear implant bypasses the hair cells and stimulates the spiral-ganglion neurons directly. So a genetic lesion confined to the cochlea(the membranous labyrinth) leaves the implant's target intact and tends to implant well; a lesion in the spiral ganglion itself damages that target and may not. This is the spiral-ganglion hypothesis, and it turns genetic testing into a prognostic tool.[2012]
FChapter roadmap
| Movement | Modules | What they cover |
|---|---|---|
| The genetics | 2–5 | Syndromic vs non-syndromic; patterns of inheritance; GJB2 and the connexins; the landscape of deafness genes by where they act. |
| Testing | 6–7 | From Sanger sequencing to next-generation panels; and how genetic testing fits the cochlear-implant work-up. |
| Predicting the result | 8–10 | The spiral-ganglion hypothesis; genotype-specific outcomes; and auditory neuropathy & OTOF. |
| People & the future | 11–12 | Counselling, recurrence and ethics; and the gene-therapy horizon. |
We begin by drawing the first and most clinically useful distinction — syndromic versus non-syndromic deafness (Module 2).
What is the best account of why outcomes vary, and what could narrow the uncertainty before surgery?
Roughly how common is congenital hearing loss, and how much is genetic?
What is this chapter's central organising idea linking genetics to implant outcome?